Last reviewed · How we verify
Ropivacaine and dexamethasone — Competitive Intelligence Brief
phase 3
Local anesthetic with corticosteroid adjuvant
Voltage-gated sodium channels; glucocorticoid receptor
Anesthesia/Pain Management
Small molecule
Live · refreshed every 30 min
Target snapshot
Ropivacaine and dexamethasone (Ropivacaine and dexamethasone) — University of Texas Southwestern Medical Center. Ropivacaine provides local anesthesia by blocking sodium channels in nerve fibers, while dexamethasone reduces inflammation and prolongs the duration of the anesthetic effect.
Comparator set (5 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Ropivacaine and dexamethasone TARGET | Ropivacaine and dexamethasone | University of Texas Southwestern Medical Center | phase 3 | Local anesthetic with corticosteroid adjuvant | Voltage-gated sodium channels; glucocorticoid receptor | |
| Ropivacaine + dexamethasone | Ropivacaine + dexamethasone | Sahiwal medical college sahiwal | marketed | Local anesthetic with corticosteroid adjuvant | Voltage-gated sodium channels; glucocorticoid receptor | |
| Bupivacaine and Dexamethasone Injection | Bupivacaine and Dexamethasone Injection | Colette Curtis MD | marketed | Local anesthetic with corticosteroid adjuvant | Voltage-gated sodium channels (bupivacaine); glucocorticoid receptor (dexamethasone) | |
| Bupivacaine Hydrochloride combined with dexamethasone | Bupivacaine Hydrochloride combined with dexamethasone | Zhejiang Cancer Hospital | marketed | Local anesthetic with corticosteroid adjuvant | Voltage-gated sodium channels (bupivacaine); glucocorticoid receptor (dexamethasone) | |
| Bupivacaine 0.5% , Dexamethasone | Bupivacaine 0.5% , Dexamethasone | Sisli Hamidiye Etfal Training and Research Hospital | marketed | Local anesthetic with corticosteroid adjuvant | Voltage-gated sodium channels (bupivacaine); glucocorticoid receptor (dexamethasone) | |
| Ropivacaine 0.2% + Dexamethasone | Ropivacaine 0.2% + Dexamethasone | Instituto do Coracao | phase 3 | Local anesthetic with corticosteroid adjuvant | Voltage-gated sodium channels (ropivacaine); glucocorticoid receptor (dexamethasone) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Local anesthetic with corticosteroid adjuvant class)
- Colette Curtis MD · 1 drug in this class
- Instituto do Coracao · 1 drug in this class
- Sahiwal medical college sahiwal · 1 drug in this class
- Sisli Hamidiye Etfal Training and Research Hospital · 1 drug in this class
- University of Texas Southwestern Medical Center · 1 drug in this class
- Zhejiang Cancer Hospital · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Ropivacaine and dexamethasone CI watch — RSS
- Ropivacaine and dexamethasone CI watch — Atom
- Ropivacaine and dexamethasone CI watch — JSON
- Ropivacaine and dexamethasone alone — RSS
- Whole Local anesthetic with corticosteroid adjuvant class — RSS
Cite this brief
Drug Landscape (2026). Ropivacaine and dexamethasone — Competitive Intelligence Brief. https://druglandscape.com/ci/ropivacaine-and-dexamethasone. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab